What does the evidence say about Zeaxanthin Visual Performance Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Zeaxanthin Visual Performance Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - However, these approaches require repeated invasive injections and are associated with considerable economic burden and procedural risks [,]. [Wang Wei-Xiang (2026); evidence level 1] - Experimental and clinical studies have suggested that increased macular pigment levels may support visual performance and potentially attenuate AMD progression [–]. [Wang Wei-Xiang (2026); evidence level 1] - Some findings from the Age‐Related Eye Disease Study 2 (AREDS2) indicated that lutein and zeaxanthin supplementation significantly reduced the risk of progression to late‐stage AMD []. [Wang Wei-Xiang (2026); evidence level 1] - 1 2 3 4 5 6 7 Age‐related macular degeneration (AMD) remains one of the leading causes of irreversible central vision loss among individuals over 65 years of age worldwide. [Wang Wei-Xiang (2026); evidence level 1] - This narrative review critically summarizes the available evidence on how various natural bioactive compounds, such as carotenoids, polyphenols, flavonoids, omega-3 fatty acids and botanical extracts, can affect important molecular pathways associated with ocular degeneration. [De Silva S (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.